| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9833459 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(9 years from now) | |
| US10188663 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(9 years from now) | |
| US9271990 | FRESENIUS KABI USA | Fulvestrant formulations |
May, 2034
(10 years from now) | |
Fulvestrant is owned by Fresenius Kabi Usa.
Fulvestrant contains Fulvestrant.
Fulvestrant has a total of 3 drug patents out of which 0 drug patents have expired.
Fulvestrant was authorised for market use on 20 May, 2019.
Fulvestrant is available in solution;intramuscular dosage forms.
Fulvestrant can be used as treatment of hormone receptor positive advanced breast cancer in postmenopausal women.
The generics of Fulvestrant are possible to be released after 17 May, 2034.
Drugs and Companies using FULVESTRANT ingredient
Market Authorisation Date: 20 May, 2019
Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women
Dosage: SOLUTION;INTRAMUSCULAR
FULVESTRANT family patents
